de Notaristefani Carlo 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Feb 14, 2019
Insider Transaction Report
Form 4
de Notaristefani Carlo
Executive VP Global Operations
Transactions
- Award
Ordinary Shares
2019-02-12+14,432→ 17,161.727 total - Sale
Ordinary Shares
2019-02-13$17.88/sh−5,041$90,108→ 12,120.727 total - Award
Restricted Share Units
2019-02-12+1,204→ 1,204 total→ Ordinary Shares (1,204 underlying)
Footnotes (7)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The Ordinary Shares were received for no consideration upon the satisfaction of performance criteria underlying an award of performance share units.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the performance share units.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $17.88, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F7]Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time based vesting and will vest on May 16, 2019.